SL-279252 for Cancer

Recruiting in Palo Alto (17 mi)

+4 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Shattuck Labs, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

Research Team

Shattuck Labs

Principal Investigator

Shattuck Labs

Eligibility Criteria

Adults with certain advanced solid tumors or lymphomas who have tried, can't tolerate, or aren't eligible for standard treatments. They must be in relatively good health (ECOG PS of 0 or 1), not pregnant, willing to use contraception, and without a history of severe reactions to PD-1/L1 therapy. Exclusions include prior OX40 agonist treatment and specific medical conditions.

Inclusion Criteria

You have a certain type of head and neck cancer that started in the mouth, throat or voice box. If your cancer started in other places like the nose or sinuses, you cannot participate.

You are physically able to perform everyday activities and take care of yourself without assistance, or you have some symptoms but are still able to carry out daily activities with little assistance.

You cannot have had to stop a previous PD-1/L1 therapy due to side effects affecting your immune system.

See 17 more

Exclusion Criteria

You are currently breastfeeding.

Refractory to last PD-1/L1 inhibitor-based therapy.

Any anti-cancer therapy within the specified time intervals prior to first dose (D1) of SL-279252.

See 14 more

Treatment Details

Interventions

SL-279252 (PD-1/PD-L1 Inhibitor)

Trial OverviewSL-279252 is being tested in this Phase 1 trial for safety, tolerability, how the body processes it (pharmacokinetics), its effectiveness against cancer (anti-tumor activity), and biological effects on the body (pharmacodynamics). Participants will receive escalating doses to find an optimal dose that's both safe and effective.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: SL-279252Experimental Treatment1 Intervention

Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated